Cargando…
Strain Differences Determine the Suitability of Animal Models for Noninvasive In Vivo Beta Cell Mass Determination with Radiolabeled Exendin
PURPOSE: Noninvasive beta cell mass (BCM) quantification is a crucial tool to understand diabetes development and progression. [(111)In]exendin is a promising agent for in vivo beta cell imaging, but tracer testing has been hampered by the lack of well-defined rodent models. PROCEDURES: Biodistribut...
Autores principales: | Willekens, Stefanie M. A., Joosten, Lieke, Boerman, Otto C., Balhuizen, Alexander, Eizirik, Decio L., Gotthardt, Martin, Brom, Maarten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010585/ https://www.ncbi.nlm.nih.gov/pubmed/26886298 http://dx.doi.org/10.1007/s11307-016-0936-y |
Ejemplares similares
-
Non-invasive in vivo determination of viable islet graft volume by (111)In-exendin-3
por: Eter, Wael A., et al.
Publicado: (2017) -
(111)In-exendin Uptake in the Pancreas Correlates With the β-Cell Mass and Not With the α-Cell Mass
por: Brom, Maarten, et al.
Publicado: (2015) -
The effect of purification of Ga-68-labeled exendin on in vivo distribution
por: Brom, Maarten, et al.
Publicado: (2016) -
Enhanced Specific Activity by Multichelation of Exendin-3
Leads To Improved Image Quality and In Vivo Beta
Cell Imaging
por: Joosten, Lieke, et al.
Publicado: (2017) -
Graft revascularization is essential for non-invasive monitoring of transplanted islets with radiolabeled exendin
por: Eter, Wael A., et al.
Publicado: (2015)